AxoGen (NASDAQ:AXGN) Price Target Raised to $56.00

AxoGen (NASDAQ:AXGN) had its price objective boosted by Wells Fargo & Company from $48.00 to $56.00 in a report released on Thursday,Benzinga reports. The firm currently has an overweight rating on the medical equipment provider’s stock.

Several other equities analysts have also recently weighed in on AXGN. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of AxoGen in a report on Wednesday. Mizuho set a $65.00 price objective on AxoGen in a research report on Wednesday. Lake Street Capital reissued a “buy” rating on shares of AxoGen in a research note on Monday, October 5th. Bank of America initiated coverage on shares of AxoGen in a report on Monday, October 12th. They set a “buy” rating and a $52.00 target price on the stock. Finally, Canaccord Genuity Group raised their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, AxoGen presently has an average rating of “Moderate Buy” and an average price target of $57.92.

AxoGen Stock Performance

Shares of AxoGen stock opened at $49.37 on Thursday. The stock’s fifty day simple moving average is $42.86 and its 200 day simple moving average is $39.45. The company has a current ratio of 12.02, a quick ratio of 5.04 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $2.95 billion, a PE ratio of -75.95 and a beta of 1.17. AxoGen has a 12 month low of $21.68 and a 12 month high of $52.91.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.08. AxoGen had a negative return on equity of 5.35% and a negative net margin of 11.96%. The firm had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $73.45 million. On average, research analysts predict that AxoGen will post -0.44 EPS for the current year.

Insider Transactions at AxoGen

In other AxoGen news, Director Amy Wendell sold 13,353 shares of AxoGen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the sale, the director owned 107,976 shares of the company’s stock, valued at $5,228,197.92. This trade represents a 11.01% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathy Weiler sold 14,150 shares of AxoGen stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $45.30, for a total value of $640,995.00. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 98,503 shares of company stock worth $4,656,947 in the last 90 days. Company insiders own 2.44% of the company’s stock.

Institutional Investors Weigh In On AxoGen

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in AxoGen in the second quarter valued at $204,123,000. Artemis Investment Management LLP lifted its position in AxoGen by 27.5% during the third quarter. Artemis Investment Management LLP now owns 1,780,992 shares of the medical equipment provider’s stock worth $74,659,000 after acquiring an additional 384,200 shares during the last quarter. Wellington Management Group LLP lifted its holdings in AxoGen by 44.3% during the 2nd quarter. Wellington Management Group LLP now owns 1,391,654 shares of the medical equipment provider’s stock worth $64,280,000 after purchasing an additional 427,089 shares during the last quarter. Bamco Inc. NY bought a new stake in AxoGen in the 2nd quarter valued at $34,190,000. Finally, TimesSquare Capital Management LLC bought a new stake in AxoGen in the 2nd quarter valued at $31,863,000. Institutional investors own 80.29% of the company’s stock.

More AxoGen News

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Strong Q3 execution and higher guidance: AxoGen reported 26% revenue growth and 45% adjusted EBITDA growth for the third quarter of 2026. Management maintained a target of at least $290 million in 2026 sales and expects gross margin of 73% or higher, reinforcing the company’s growth and operating-leverage story. AxoGen Third-Quarter Earnings Results
• Positive Sentiment: Analysts raised their targets: Canaccord Genuity increased its price target to $60 from $55 and maintained a Buy rating. Truist also raised its target to $60 from $53, while Wells Fargo increased its target to $56 from $48 and kept an Overweight rating. HC Wainwright lifted its target to $56 from $53 and retained a Buy rating. These revisions indicate improving confidence in AxoGen’s earnings outlook. Truist AxoGen Price Target Update
• Positive Sentiment: BioCircuit acquisition expands the opportunity: An investment analysis characterized AxoGen as evolving toward a leading procedural platform in peripheral nerve repair. The planned $200 million BioCircuit, or NerveTape, acquisition is intended to reduce technical barriers for surgeons, broaden the addressable market and be accretive at an estimated 5.9 times 2027 sales. AxoGen Taking the Friction Out of Nerve Repair
• Neutral Sentiment: Valuation remains an investor debate: Coverage is focused on whether AXGN’s growth prospects justify its elevated valuation after its substantial advance. The stock’s performance relative to other medical companies may attract momentum investors, but also raises the risk that much of the near-term optimism is already reflected in the share price. Does AxoGen Have More Upside?
• Negative Sentiment: Profitability and execution risks remain: Despite improving adjusted EBITDA, AxoGen continues to report negative net income and analysts expect a full-year loss. Investors must also weigh acquisition integration, dilution and the company’s premium valuation against the possibility of slower growth.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.